Skip to main content

Lorlatinib Dosage

Medically reviewed by Drugs.com. Last updated on Sep 12, 2024.

Applies to the following strengths: 25 mg; 100 mg

Usual Adult Dose for Non-Small Cell Lung Cancer

100 mg orally once a day

Comments:


Use: For the treatment of adult patients with metastatic NSCLC whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test

Renal Dose Adjustments

Liver Dose Adjustments

Dose Adjustments

Dose Modifications for Adverse Reactions:


Central Nervous System Adverse Effects:

Hyperlipidemia:
Grade 4 hypercholesterolemia OR Grade 4 hypertriglyceridemia: Withhold until recovery to Grade 2 or less; resume at same dose. If severe hypercholesterolemia and/or hypertriglyceridemia recurs, resume at reduced dose.

Atrioventricular (AV) Block:

Interstitial Lung Disease (ILD)/Pneumonitis:

Hypertension:
Grade 4 (life-threatening consequences, urgent intervention indicated): Withhold until recovery to Grade 1 or less, and resume at a reduced dose or permanently discontinue. Permanently discontinue, if Grade 4 hypertension recurs.

Hyperglycemia:
Grade 3 (greater than 250 mg/dL) despite optimal anti-hyperglycemic therapy OR Grade 4: Withhold until hyperglycemia is adequately controlled, then resume at the next lower dosage. If adequate hyperglycemic control cannot be achieved with optimal medical management, permanently discontinue

Other Adverse Reactions:

Concomitant Use of Strong CYP450 3A Inducers:
Concomitant Use of Moderate CYP450 3A Inducers:

Dose Modification for Strong CYP450 3A Inhibitors:

Precautions

CONTRAINDICATIONS:


Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:


Storage requirements:

Monitoring:

Patient advice:

Frequently asked questions

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.